Mesoblast Limited - American Depositary Shares (MESO)

Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted quarterly earnings of $1.86 per share, beating market estimates of 98 cents per share.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and manufacturing controls.

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028).

Mesoblast Limited (NASDAQ:MESO) stock is trading higher Thursday after the company announced the U.S. Food and Drug Administration (FDA) approved Ryoncil.

U.S. stock futures climbed on Thursday in premarket hours after a hawkish cut from the Federal Reserve on Wednesday.

The company will soon launch Ryoncil for children at least 2 months old with acute graft versus host disease.